조류인플루엔자 치료 시장 : 제품 유형별, 투여 경로별, 최종 사용자별, 용도별 시장 예측(2026-2032년)

The Bird Flu Treatment Market is projected to grow by USD 19.75 billion at a CAGR of 6.72% by 2032.

Bird Flu Treatment Market Executive Summary

Bird flu treatment is moving from an episodic public health concern to a strategic priority for governments, pharmaceutical manufacturers, healthcare systems, and animal health stakeholders. Human infections with avian influenza A viruses such as H5N1, H7N9, and other zoonotic subtypes remain uncommon, but the clinical stakes are high: WHO surveillance has documented more than 900 human H5N1 cases since 2003, with historically high case fatality among reported infections.

Current treatment strategies emphasize rapid antiviral initiation, supportive clinical care, infection prevention, and coordinated One Health surveillance across poultry, wild birds, mammals, and humans. The market demand is being shaped by neuraminidase inhibitors such as oseltamivir, zanamivir, and peramivir, investigational therapeutics, diagnostic testing, antiviral stockpiling, and pandemic preparedness programs.

Transformative Shifts in Bird Flu Treatment

The bird flu treatment landscape is being reshaped by wider geographic spread of highly pathogenic avian influenza, growing mammalian detections, and heightened concern over zoonotic spillover. Since 2021, H5N1 clade 2.3.4.4b has driven extensive outbreaks in wild birds and poultry across multiple regions, increasing demand for faster detection, early treatment protocols, and stronger antiviral readiness.

Treatment pathways are also shifting from hospital-centered response to integrated preparedness. Governments and health systems are strengthening antiviral reserves, updating clinical guidance, expanding sequencing capacity, and connecting veterinary surveillance with human health alert systems. This transition is creating new opportunities for antiviral manufacturers, diagnostic developers, cold-chain providers, and clinical research organizations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly important in avian influenza response because treatment decisions depend on speed, subtype identification, and risk assessment. AI-enabled genomic surveillance can help flag mutations associated with mammalian adaptation, antiviral resistance, or antigenic drift, allowing public health agencies and manufacturers to prioritize candidate countermeasures more efficiently.

In clinical and commercial settings, AI can support outbreak forecasting, hospital triage workflows, drug repurposing, pharmacovigilance, and supply planning for antivirals and diagnostics. The cumulative impact is strongest when AI outputs are validated against laboratory-confirmed data, transparent epidemiological models, and regulatory-grade evidence rather than used as stand-alone decision tools.

Key Regional Insights

Asia-Pacific remains a critical region for bird flu treatment because it has experienced repeated human infections linked to avian influenza subtypes, including H5N1 and H7N9, alongside dense poultry production, live bird market exposure, and high-volume regional trade in several countries. North America has intensified preparedness following widespread H5N1 detections in wild birds, poultry, mammals, and U.S. dairy cattle, increasing emphasis on occupational monitoring, antivirals, diagnostic access, and risk communication for exposed workers.

Europe continues to invest in surveillance and cross-border response through public health and animal health coordination, while Latin America has expanded attention to poultry protection, wildlife monitoring, and treatment readiness after regional H5N1 incursions in birds and marine mammals. The Middle East's risk profile is linked to migratory bird routes, poultry imports, live animal movement, and healthcare preparedness, whereas Africa faces added challenges from limited laboratory capacity, uneven antiviral availability, underreported outbreaks, and the need for stronger One Health infrastructure.

Key Group Insights

ASEAN markets are central to bird flu treatment demand because poultry density, cross-border trade, live bird market interfaces, and historical avian influenza outbreaks require integrated surveillance and rapid access to antivirals. The GCC is prioritizing health security, import controls, hospital preparedness, and high-capacity public-sector procurement, supported by interest in advanced diagnostics and coordinated emergency response systems.

The European Union benefits from harmonized animal disease reporting, centralized regulatory pathways, coordinated preparedness planning, and established laboratory networks, making it a major reference point for avian influenza response standards. BRICS countries represent a large treatment opportunity due to population scale, poultry production intensity, vaccine and pharmaceutical manufacturing capacity, and varied exposure to poultry and wildlife reservoirs. G7 and NATO members influence antiviral stockpiling, research funding, biosurveillance interoperability, supply chain resilience, and emergency response coordination across allied healthcare, agriculture, and defense systems.

Key Country Insights

The United States is prioritizing H5N1 surveillance, antiviral guidance, occupational risk monitoring, and coordination between public health, agriculture, and dairy operations, while Canada is focused on wildlife, poultry, and public health coordination supported by national surveillance systems. Mexico and Brazil are important due to poultry production scale, regional trade exposure, and the need to protect food supply chains. The United Kingdom, Germany, France, Italy, and Spain continue to strengthen surveillance, laboratory capacity, antiviral readiness, and preparedness through European public health and animal health frameworks.

Russia's geographic scale, poultry sector, and migratory bird pathways make monitoring strategically important. China and India combine large poultry sectors, dense population interfaces, prior avian influenza experience, and substantial domestic pharmaceutical capacity, making them central to treatment access and outbreak control. Japan, Australia, and South Korea maintain advanced diagnostics, strict biosecurity, national stockpiling policies, and strong public health systems that support rapid clinical response, subtype confirmation, and antiviral deployment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based antiviral portfolios, scalable manufacturing, and resilient supply chains for oseltamivir and other clinically relevant influenza therapeutics. Companies should align product strategy with CDC, WHO, and national clinical guidance emphasizing early treatment for suspected or confirmed human avian influenza, particularly among patients with high-risk exposure, severe disease, or occupational contact with infected animals.

Executives should invest in companion diagnostics, resistance monitoring, genomic surveillance partnerships, and real-world evidence generation. Commercial teams can strengthen market positioning by supporting government stockpiles, hospital protocols, occupational health programs, pharmacist education, cold-chain readiness, and One Health collaborations that connect poultry producers, veterinarians, laboratories, and public health agencies.

Research Methodology

This executive summary is based on secondary research from verified public health, regulatory, and scientific sources, including WHO, CDC, WOAH, FAO, national health agencies, peer-reviewed literature, and official surveillance updates. The analysis emphasizes clinically accepted treatment approaches, documented outbreak patterns, regional preparedness indicators, antiviral resistance considerations, diagnostic capacity, and publicly available evidence on avian influenza epidemiology.

The methodology applies a structured market intelligence framework that triangulates disease surveillance, treatment guidance, policy developments, procurement behavior, technology adoption, and One Health response priorities. Insights are synthesized to support strategic planning across pharmaceuticals, diagnostics, healthcare delivery, animal health, and government preparedness without relying on speculative or unverified claims.

Conclusion

Bird flu treatment demand is being driven by the convergence of zoonotic risk, expanding surveillance, antiviral preparedness, and the need for faster clinical response. Although human cases remain rare, the severity of reported infections and the global spread of highly pathogenic avian influenza justify sustained investment in therapeutics, diagnostics, stockpiling, and One Health infrastructure.

The strongest market opportunities will favor organizations that combine regulatory readiness, scientific credibility, scalable production, validated diagnostics, and public-sector collaboration. As AI, genomic sequencing, and integrated surveillance mature, the bird flu treatment landscape is expected to become more proactive, data-driven, and preparedness-oriented.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Bird Flu Treatment Market, by Product Type

• 7.1. Antiviral Drug
  • 7.1.1. Adamantanes
  • 7.1.2. Combination Therapy
  • 7.1.3. Neuraminidase Inhibitors
  • 7.1.4. Polymerase Inhibitors
• 7.2. Supportive Care
  • 7.2.1. Oxygen Therapy
  • 7.2.2. Rehydration Therapy
  • 7.2.3. Symptom Management
  • 7.2.4. Telehealth Monitoring
• 7.3. Vaccine
  • 7.3.1. Inactivated Vaccine
  • 7.3.2. Live Attenuated Vaccine
  • 7.3.3. Mrna Vaccine
  • 7.3.4. Recombinant Vaccine

8. Bird Flu Treatment Market, by Administration Route

• 8.1. Inhalation
  • 8.1.1. Dry Powder Inhaler
  • 8.1.2. Metered Dose Inhaler
  • 8.1.3. Nebulizer
• 8.2. Injectable
  • 8.2.1. Intramuscular
  • 8.2.2. Nanoparticle Delivery
  • 8.2.3. Subcutaneous
• 8.3. Intravenous
  • 8.3.1. Central Line
  • 8.3.2. Peripheral Line
  • 8.3.3. Smart Infusion Pumps
• 8.4. Oral
  • 8.4.1. Capsule
  • 8.4.2. Sublingual
  • 8.4.3. Suspension
  • 8.4.4. Tablet

9. Bird Flu Treatment Market, by End User

• 9.1. Clinics
  • 9.1.1. Community Health Centers
  • 9.1.2. Outpatient Clinics
  • 9.1.3. Specialty Clinics
• 9.2. Hospitals
  • 9.2.1. Private Hospitals
  • 9.2.2. Public Hospitals
  • 9.2.3. Specialized Care Centers
• 9.3. Laboratories
  • 9.3.1. Hospital Labs
  • 9.3.2. Independent Labs
  • 9.3.3. Point Of Care Testing
• 9.4. Pharmacies
  • 9.4.1. Mail Order Pharmacies
  • 9.4.2. Online Pharmacies
  • 9.4.3. Retail Pharmacies

10. Bird Flu Treatment Market, by Application

• 10.1. Animal Health
  • 10.1.1. Livestock
  • 10.1.2. Poultry
  • 10.1.3. Wild Birds
• 10.2. Human Health
  • 10.2.1. Adult Patients
  • 10.2.2. Geriatric Patients
  • 10.2.3. Pediatric Patients

11. Bird Flu Treatment Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Bird Flu Treatment Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Bird Flu Treatment Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Alltech, Inc.
• 15.2. BioCryst Pharmaceuticals, Inc.
• 15.3. Boehringer Ingelheim International GmbH
• 15.4. Ceva Sante Animale
• 15.5. Cipla Limited
• 15.6. CSL Limited
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. FATRO S.p.A.
• 15.9. Gilead Sciences, Inc.
• 15.10. GlaxoSmithKline PLC
• 15.11. Hester Biosciences Limited
• 15.12. Johnson & Johnson Services, Inc.
• 15.13. Macleods Pharmaceuticals Ltd
• 15.14. Merck KGaA
• 15.15. Moderna, Inc.
• 15.16. Novartis AG
• 15.17. PetSmart LLC
• 15.18. Pfizer Inc.
• 15.19. Sanofi S.A.
• 15.20. Serum Institute of India Pvt. Ltd.
• 15.21. Sinovac Biotech Ltd.
• 15.22. Takeda Pharmaceutical Company Limited
• 15.23. Tianjin Ringpu Biotechnology Co. Ltd.
• 15.24. Yebio Bioengineering Co. Ltd.
• 15.25. Zoetis Inc.